Organization & Developments: Orexigen

Parents

2011: Orexigen Fails to Win FDA Approval of Obesity Drug, Stock Crashes
2011: Orexigen, Facing High Hurdle at FDA, Puts Obesity Drug Development on Hold; Shares Tank (2011)
2016: Orexigen De-Listing: What You Need To Know - Orexigen Therapeutics, Inc. (NASDAQ:OREX)
2016: Orexigen Partnering With Valeant May Bring Bad Mojo - Orexigen Therapeutics, Inc. (NASDAQ:OREX)
2016: Orexigen Pulls The Plug On Post-Marketing Cardiovascular Trial - Orexigen Therapeutics, Inc. (NASDAQ:OREX)
2016: Recent Deals Point To Long-Term Concerns At Orexigen Therapeutics - Orexigen Therapeutics, Inc. (NASDAQ:OREX)
2017: VA_65--Orexigen Therapeutics Contract Award Effective 3/01/2017 65IB, V797D-70103 Effective 3/1/2017
2018: Bankrupt and weary, diet pill maker Orexigen to sell for $75M to Nalpropion – Endpoints News
2018: With debt looming, browbeaten diet pill maker Orexigen goes bankrupt
Biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of centr
Orexigen develops and screens rational drug combinations based on the company's proprietary understanding of how the brain contr
OREXIGEN'S goal is to develop and commercialize new, proprietary combinations of currently available drugs that are designed to